Global drugmakers' stocks dropped across the board after U.S. President Donald Trump reiterated plans for a "major" tariff on ...

This contradicts the White House’s initial fact sheet, which excluded pharma from the list alongside copper, semiconductors, and lumber. The proposed tariffs, reportedly set at 26 per cent on select ...

Analysts see this move as a strong tailwind for Indian pharma companies, which continue to benefit from their dominant position in the global generics market. Leading pharma stocks recorded ...

Indian pharma stocks, including Sun Pharmaceutical Industries, Gland Pharma, Lupin and others traded sharply lower on Wednesday after the US President Donald Trump said he will soon announce a ...

Innate Pharma (IPHA) announced a EUR 15M capital increase subscribed by Sanofi (SNY). As announced on April 23 and given the satisfactory market conditions, Sanofi has agreed to subscribe to ...

UroGen Pharma (URGN) announced patient-reported outcomes following treatment of patients with low-grade intermediate-risk non-muscle invasive bladder cancer, LG-IR-NMIBC, that showed ...

Currently, too, the US does not impose any tariff on pharma product imports from India. The US is India’s largest export market for pharmaceutical goods, so the exemption brings huge relief to ...

Fierce Pharma’s Fraiser Kansteiner sits down with KPMG’s life sciences sector leader Kristin Pothier, who discusses how the current tariffs could pose challenges, how drugmakers and other life ...

Indian pharma stocks were in focus on Thursday (April 3, 2025) early trading hours after the generic drugmakers got an exemption from U.S. tariff levy. Also read: Front-end manufacturing in U.S ...

Thanks to David Krumholtz of "The Santa Clause" fame, we've gotten our very first glimpse at the official logo for next year's "Supergirl: Woman of Tomorrow"... or perhaps just "Supergirl"?

Pharma stocks crashed 6 per cent before closing 4 per cent lower on Friday after US President Donald Trump reportedly threatened tariffs on pharma products at “levels never seen before.” ...

Sumitomo’s Asia pharma business is comprised of three outfits across China and in Singapore and achieved estimated 2024 revenues of 45.8 billion yen ($305 million) in 2024. Related ...